Effect of Ribose Cysteine Pretreatment on Hepatic and Renal Acetaminophen Metabolite Formation and Glutathione Depletion

Abstract

Ribose cysteine (2(R,S)-D-ribo-(1ø,2ø,3ø,4ø-tetrahydroxybutyl)thiazolidine-4(R)-carboxylic acid) protects against acetaminophen-induced hepatic and renal toxicity. The mechanism for this protection is not known, but may involve inactivation of the toxic electrophile via enhancement of glutathione (GSH) biosynthesis. Therefore, the goal of this study was to determine if GSH biosynthesis was required for the ribose cysteine protection. Male CD-1 mice were injected with either acetaminophen or acetaminophen and ribose cysteine. The ribose cysteine cotreatment antagonized the acetaminophen-induced depletion of non-protein sulfhydryls in liver as well as GSH in kidney. Moreover, ribose cysteine cotreatment significantly increased the concentration of acetaminophen-cysteine, hepatic acetaminophen-mercapturate in liver and renal acetaminophen-GSH metabolites in kidney 4 hr after acetaminophen. To determine whether protection against acetaminophen-induced liver and kidney damage involved ribose cysteine dependent GSH biosynthesis, buthionine sulfoximine was used to selectively block g-glutamylcysteine synthetase (g-GCS). Plasma sorbitol dehydrogenase (SDH) activity and blood urea nitrogen from mice pretreated with buthionine sulfoximine and challenged with acetaminophen indicated that both liver and kidney injury had occurred. While co-treatment with ribose cysteine had previously protected against acetaminophen-induced liver and kidney injury, it did not diminish the acetaminophen-induced damage to either organ in the buthionine sulfoximine-treated mice. In conclusion, ribose cysteine serves as a cysteine prodrug that facilitates GSH biosynthesis and protects against acetaminophen-induced target organ toxicity.

Irbesartan mitigates acute liver injury, oxidative stress, and apoptosis induced by acetaminophen in mice

“…[ 2 ] Various mechanisms were proved to participate in NAPQI‐induced hepatotoxicity. [ 3 ] Numerous studies have indicated that NAPQI attributes to release of excessive reactive oxygen species (ROS). Moreover, ROS leads to enhanced lipid peroxidation and oxidative stress that have been confirmed to participate in APAP‐induced acute hepatotoxicity.…”

Ribose-cysteine protects against the development of atherosclerosis in apoE-deficient mice

“…Ribose-cysteine is a registered therapeutic goods approved dietary supplement which gives a slower more controlled release of L-cysteine than NAC reducing the potential for toxicity [19]. However, studies on ribose-cysteine are limited and its affect mainly only studied in acute oxidative stress conditions in rodents where it has been shown to increase GSH levels in multiple tissues without toxicity [34,35]. Only one study has investigated the longer term effect of ribose-cysteine showing that daily supplementation (4 mg/day) in the Lp(a) mouse model of hyperlipidaemia for 8 weeks promotes a significant increase in GSH and GPx in the liver and blood, without toxicity [20].…”

Protective Effects of Pterostilbene against Acetaminophen‐Induced Hepatotoxicity in Rats

“…However, when taken in excess, it produces severe hepatotoxicity, which is often fatal . Under normal conditions, acetaminophen is metabolically activated by cytochrome P450 2E1 to form a reactive metabolite, N ‐acetyl‐ p ‐benzoquinone imine (NAPQI) . At therapeutic doses, NAPQI is efficiently detoxified, principally by conjugation with glutathione (GSH) under glutathione S ‐transferase (GST)‐mediated conditions to the 3‐glutathione‐ S ‐yl‐acetaminophen conjugate that excreted by the kidney .…”